We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Events

26 Oct 2026 - 29 Oct 2026
16 Nov 2026 - 19 Nov 2026

Alliance to Develop Drug for Asthma, COPD

By HospiMedica staff writers
Posted on 16 Nov 2004
An agreement to collaborate on commercializing a new drug for asthma and chronic obstructive pulmonary disease (COPD) has been announced by Glenmark Pharmaceuticals S.A., a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL, Mumbai, India) and Forest Laboratories, Inc. More...
(New York, NY).

GRC 3886 is a novel, orally available phosphodiesterase 4 (PDE4) inhibitor being developed for chronic COPD and asthma by Glenmark. PDE4 inhibitors target the underlying cause of both COPD and asthma by blocking inflammation through a nonsteroid dependent mechanism. GRC 3886 is now entering phase I clinical trials in the United Kingdom. In preclinical studies, the compound appears to be effective and well tolerated when given at pharmacologic doses.

Forest will develop, register, and commercialize the compound for use in North America, while Glenmark will retain commercialization rights for the rest of the world. Forest will make an upfront payment to Glenmark upon initiation of the agreement, will make other milestones payments, and will earn a royalty on net sales of the product.

"Forest has consistently demonstrated exceptional development, sales, and marketing skills and we are very excited to partner with them on this product,” said Glen Saldanha, M.D., CEO of Glenmark.



Related Links:
Glenmark
Forest

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Pediatric Mask
Respire SOFT
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image:The NCIBT team with the cath lab members celebrating the completion of the study. (Image Credit: UC Davis)

Dual-Imaging Catheter Completes Initial Human Evaluation of Coronary Plaque

Atherosclerosis involves plaque buildup in arterial walls that can narrow blood vessels and increase the risk of heart attack, stroke, and other serious cardiovascular conditions. In coronary arteries,... Read more

Patient Care

view channel
Image: Researchers evaluated the Omni 128 cm long-axial field-of-view PET/CT system, which captures more of the body and radiotracer signal at once, potentially enabling shorter scans. (Photo courtesy of GE HealthCare)

Total-Body PET/CT Scanner Enables One-Minute Diagnostic-Quality Cancer Imaging

Positron emission tomography/computed tomography (PET/CT) combines radiotracer-based functional imaging with anatomical detail to diagnose, stage, and monitor cancer. Conventional scanners image the body... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.